Search press releases
Every release here is real and links to its original. Filter by company, topic, language and date.
- Coverys Reveals 68% of Inpatient Diagnostic Errors Occur on General Medical-Surgical UnitsA Coverys report reveals 68% of inpatient diagnostic errors occur on general med-surg units, highlighting key vulnerabilities and risk solutions.
- Neu ins Leben gerufene International Brain Health Coalition soll bewährte Strategien in die Praxis umsetzenWeltweit führende Akteure aus den Bereichen Medizin, Biowissenschaften, Technologie, Finanzen und den Vereinten Nationen schließen sich zusammen, um Erkenntnisse zur Gehirngesundheit in Haushalte, Gemeinden und Gesundheitssysteme zu tragen: Umwandlung von Erkenntnissen in Gerechtigkeit....
- PharmaTher Holdings Ltd.PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINESHighlightsM3DICINES™ 3D-printed medicines platform. One platform for PharmaTher's proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label products, formulation licensing and clinical trial supply.Commercial launch of M3DICINES™. Initial orders of the CraftMake™ pharmaceutical 3D printer, the platform's entry point, are planned for Q4 2026.Near-term products. First proprietary 503A peptide products are planned for Q4 2026, followed by a ketamine...
- Forward TherapeuticsForward Therapeutics Announces Positive Phase 1 Data for Potential Best-in-Class Oral TNFR1 Signaling Inhibitor FT2109, Supporting Advancement into Phase 2 DevelopmentForward Therapeutics, Inc. (“Forward” or the “Company”), a clinical-stage biotechnology company developing oral small molecule therapies for inflammation-driven diseases, today announced positive Phase 1 clinical and preclinical data for FT2109, its novel, potential best-in-class oral selective TNFR1 signaling inhibitor. The data are included in two abstracts accepted for presentation at the American College of Rheumatology (ACR) Convergence 2026, taking place November 6–11 in Orlando, Florida.
- Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of AcromegalyTrial follows promising MAR002 Phase 1 clinical trial results that demonstrated deep and durable IGF-1 suppression with PK properties that may enable dosing as infrequently as once every two weeks, compared to the daily subcutaneous injections required by the current standard of care
- OnCusp Therapeutics Announces Positive Phase 1b Data Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Resistant Ovarian Cancer (PROC) Presented at Plenary Oral Session of the IGCS 2026 Annual Global MeetingInitial Phase 1b data highlight promising clinical activity in patients with PROC and support continued clinical development of CUSP06
- Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom– Expands patient access to opioid-sparing pain control and advances 5x30 strategy –
- Cerevance, Inc.Cerevance Appoints Karl Kieburtz, M.D., M.P.H., as Chief Medical OfficerAppointment solidifies Cerevance’s leadership team as the company advances solengepras through Phase 3 development in Parkinson’s disease
- Rani Therapeutics, LLCRani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)~ Acceptance into ETP enables early FDA engagement to support development of the RaniPill® platform technology ~
- SofWave Medical, Ltd.Sofwave to Participate in the Jefferies Private MedTech Virtual SummitSofwave Medical Ltd (“the Company”) (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, today announced that Louis Scafuri, Chief Executive Officer, and Assaf Korner, Chief Financial Officer, will participate in the Jefferies Private MedTech Virtual Summit on October 7 – 8, 2026.
- Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease-- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation in ATP7B, the most prevalent Wilson disease-causing mutation in North America and Europe --